{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:10:46Z","timestamp":1787019046941,"version":"build-2736575974"},"reference-count":24,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Zoledronic acid every 4 weeks (Q4wk) reduces the incidence of skeletal-related events (SREs) in patients with metastatic lung cancer. Lung cancer patients were excluded from extended-interval dosing trials (every 12 weeks [Q12wk]) that demonstrated noninferiority of the 2 dosing schemes. To date, the optimal dosing of zoledronic acid in metastatic lung cancer remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To determine whether zoledronic acid dosed Q12wk is similar to Q4wk dosing for prevention of SRE in patients with metastatic lung cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective analysis was performed in patients with non\u2013small-cell lung cancer and small-cell lung cancer with bone metastases who received Q12wk and Q4wk zoledronic acid. The primary outcome was incidence of SRE at 1 year. Secondary analyses included time to first SRE, overall survival (OS), incidence of osteonecrosis of the jaw (ONJ), kidney dysfunction, and hypocalcemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 34 patients received Q12wk and 46 patients received Q4wk zoledronic acid. Incidence of SRE at 1 year (Q12wk, 23.5%, vs Q4wk, 23.9%; 95% CI = \u22120.184 to 0.192; P = 0.968) and median time to SRE (not reached for either cohort; P = 0.530) did not differ. The Q12wk cohort had longer median OS (24.00 vs 8.97 months; P = 0.022). There were no differences in incidence of ONJ, kidney dysfunction, and hypocalcemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>This is the first report examining extended-interval dosing of zoledronic acid in metastatic lung cancer. Incidence and time to SRE at 1 year were similar. This extended-interval dosing may be safe and reasonable for patients with lung cancer with bone metastases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1060028020967629","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T03:30:32Z","timestamp":1602905432000},"page":"697-704","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non\u2013Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0287-5623","authenticated-orcid":false,"given":"Andrew H.","family":"Tam","sequence":"first","affiliation":[{"name":"University of Michigan College of Pharmacy, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison J.","family":"Schepers","sequence":"additional","affiliation":[{"name":"University of Michigan College of Pharmacy, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Qin","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria R.","family":"Nachar","sequence":"additional","affiliation":[{"name":"University of Michigan College of Pharmacy, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,10,17]]},"reference":[{"key":"bibr1-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2012.12.004"},{"key":"bibr2-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-007-0051-0"},{"key":"bibr3-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5534-3"},{"key":"bibr4-1060028020967629","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2017.321"},{"key":"bibr5-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.08.022"},{"key":"bibr6-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1586\/era.13.15"},{"key":"bibr7-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009327"},{"key":"bibr8-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.105"},{"key":"bibr9-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20308"},{"key":"bibr10-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1177\/1758834011420599"},{"key":"bibr11-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.19.1458"},{"key":"bibr12-1060028020967629","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.924117"},{"key":"bibr13-1060028020967629","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2218-6751.2014.05.01"},{"key":"bibr14-1060028020967629","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.05.58"},{"key":"bibr15-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.8670"},{"key":"bibr16-1060028020967629","volume":"15","author":"Rosen LS","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"bibr17-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010101)91:1<144::aid-cncr19>3.0.co;2-q"},{"key":"bibr18-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19425"},{"key":"bibr19-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70174-8"},{"key":"bibr20-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.6316"},{"key":"bibr21-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.01.065"},{"key":"bibr22-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0793-8"},{"key":"bibr23-1060028020967629","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.786"},{"key":"bibr24-1060028020967629","unstructured":"RED BOOK Online. Micromedex Healthcare Series [database online]. Active Ingredient: Zoledronic Acid. Truven Health Analytics; 2020. Accessed June 11, 2020. https:\/\/www.micromedexsolutions.com\/home\/dispatch"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020967629","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020967629","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020967629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:57Z","timestamp":1777374957000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020967629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,17]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1177\/1060028020967629"],"URL":"https:\/\/doi.org\/10.1177\/1060028020967629","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,17]]}}}